시장보고서 | 연간정보서비스 | 맞춤형시장조사 | 메일링 | 비교리스트
세계의 수술 후 메스꺼움 및 구토 시장 보고서(2025년)
Post-Operative Nausea And Vomiting Global Market Report 2025
상품코드 : 1731001
리서치사 : The Business Research Company
발행일 : On Demand Report
페이지 정보 : 영문 175 Pages
 라이선스 & 가격 (부가세 별도)
US $ 4,490 ￦ 6,183,000
PDF (Single User License) help
PDF 보고서를 1명만 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.
US $ 6,490 ￦ 8,938,000
PDF (Site License) help
PDF 보고서를 동일 사업장의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.
US $ 8,490 ￦ 11,692,000
PDF (Enterprise License) help
PDF 보고서를 동일 기업의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.


ㅁ Add-on 가능: 고객의 요청에 따라 일정한 범위 내에서 Customization이 가능합니다. 자세한 사항은 문의해 주시기 바랍니다.
ㅁ 보고서에 따라 최신 정보로 업데이트하여 보내드립니다. 배송기일은 문의해 주시기 바랍니다.

한글목차

수술 후 메스꺼움 및 구토 시장 규모는 향후 수년간 강력한 성장이 전망됩니다. 2029년에는 CAGR 7.0%로 성장할 전망이며, 29억 7,000만 달러로 성장이 예측됩니다. 예측 기간 동안의 성장은 의약품 수요 증가, 병용 요법 대두, 의식의 고조 및 헬스케어 투자, 노인 인구 증가, 암 환자 수의 증가에 기인하고 있습니다. 이 기간에 예상되는 주요 동향으로는 구토 억제 치료의 진보, 전략적 제휴, 혁신적인 약제 처방, 고도 진단 툴의 통합, 전자 시뮬레이션 기기의 개발 등이 있습니다.

외과 수술 증가는 수술 후 메스꺼움 및 구토 시장의 성장을 가속할 것으로 예측됩니다. 외과적 처치는 손상된 조직, 장기 또는 이상을 진단, 치료 또는 절단이나 조작을 통해 제거하기 위한 도구를 이용하는 의료 개입을 포함합니다. 외과 수술 증가는 의료 기술 진보에 의한 것으로 수술의 안전성, 유효성, 저침습성이 향상되어 환자에게 받아들여져 적용 범위가 넓어지고 있습니다. 수술 후 메스꺼움 및 구토의 효과적인 관리는 환자의 쾌적성 향상, 회복시간 단축, 합병증 최소화, 수술 후 케어의 원활화를 통해 외과 수술을 강화하고 최종적으로 수술 성적 향상으로 이어집니다. 예를 들어 2024년 11월 호주 보건복지연구소(Australian Institute of Health and Welfare)는 2023-2024년 동안 공립병원 선택수술 대기자 명단에서 수술을 위해 입원한 환자는 77만 1,600명으로 2022-2023년 대비 4.9% 증가했다고 보고했습니다. 이 동향은 수술 건수의 증가를 부각시키고 있으며, 수술 후 메스꺼움 및 구토 시장의 확대에 박차를 가하고 있습니다.

수술 후 메스꺼움 및 구토 시장의 각사는 선진적인 유제 제제와 서방형 기술을 이용한 중요한 주사약의 개발에 주력하여 치료 효과를 향상시키고 수술환자의 증상을 장시간 완화하고 있습니다. 이러한 중요한 주사약은 주사를 통해 투여되며, 위중하거나 긴급한 병세에 즉각적이고 효과적인 치료를 제공하기 위해 필수적인 약제입니다. 예를 들면, 2024년 7월, 미국의 전문 제약회사인 아베나시사는, 0.25 mg/5 mL 단회 투여 바이알이 들어 있는 팔로노세트론 염산염 주사액을 발매했습니다. 이 제제는 헬스케어 공급자가 투여 실수를 줄이고 환자의 안전성을 향상시키는 데 도움이 됩니다. 이 주사제는 화학요법에 의한 메스꺼움 및 구토 예방이나 수술 후 24시간까지의 수술 후 메스꺼움과 구토 관리에 사용되며, 이러한 증상의 위험을 안고 있는 환자에게 신뢰성 높은 치료 선택지를 제공합니다.

목차

제1장 주요 요약

제2장 시장 특징

제3장 시장 동향 및 전략

제4장 시장-거시경제 시나리오 금리, 인플레이션, 지정학, 신형 코로나 바이러스 감염의 영향과 회복이 시장에 미치는 영향을 포함한 거시경제 시나리오

제5장 세계의 성장 분석 및 전략 분석 프레임워크

제6장 시장 세분화

제7장 지역별 및 국가별 분석

제8장 아시아태평양 시장

제9장 중국 시장

제10장 인도 시장

제11장 일본 시장

제12장 호주 시장

제13장 인도네시아 시장

제14장 한국 시장

제15장 서유럽 시장

제16장 영국 시장

제17장 독일 시장

제18장 프랑스 시장

제19장 이탈리아 시장

제20장 스페인 시장

제21장 동유럽 시장

제22장 러시아 시장

제23장 북미 시장

제24장 미국 시장

제25장 캐나다 시장

제26장 남미 시장

제27장 브라질 시장

제28장 중동 시장

제29장 아프리카 시장

제30장 경쟁 구도 및 기업 프로파일

제31장 기타 주요 기업 및 혁신 기업

제32장 세계 시장 경쟁 벤치마킹 및 대시보드

제33장 주요 인수합병(M&A)

제34장 최근 시장 동향

제35장 시장의 잠재력이 높은 국가, 부문 및 전략

제36장 부록

AJY
영문 목차

영문목차

Post-operative nausea and vomiting (PONV) is a common complication that typically occurs within 24 to 48 hours after surgery, often triggered by anesthesia, pain medications, or the body's response to surgical stress. This condition can significantly hinder a patient's recovery, leading to discomfort, delayed healing, and an increased risk of complications such as dehydration or electrolyte imbalances.

The main treatments for post-operative nausea and vomiting include serotonin antagonists, steroids, dopamine antagonists, neurokinin NK-1 receptor antagonists, non-pharmacological treatments, and others. Serotonin antagonists are medications that block serotonin receptors, preventing nausea and vomiting signals from reaching the brain. The various routes of administration include oral, intravenous, transdermal, and others, catering to different patient demographics such as pediatric, adult, and geriatric patients. Surgical procedures where PONV treatments are commonly used include orthopedic, gynecological, general, cardiac, and ophthalmic surgeries. These treatments are utilized by a range of end-users, including hospitals, ambulatory surgical centers, specialty clinics, and others.

The post-operative nausea and vomiting market research report is one of a series of new reports from The Business Research Company that provides post-operative nausea and vomiting market statistics, including post-operative nausea and vomiting industry global market size, regional shares, competitors with a post-operative nausea and vomiting market share, detailed post-operative nausea and vomiting market segments, market trends and opportunities, and any further data you may need to thrive in the post-operative nausea and vomiting industry. This post-operative nausea and vomiting market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The post-operative nausea and vomiting market size has grown strongly in recent years. It will grow from $2.11 billion in 2024 to $2.26 billion in 2025 at a compound annual growth rate (CAGR) of 7.4%. The growth during the historic period can be attributed to increased research and development activities, a rising demand for advanced therapies, higher healthcare expenditures, a growing focus on personalized medicine, and the expanding adoption of digital health technologies.

The post-operative nausea and vomiting market size is expected to see strong growth in the next few years. It will grow to $2.97 billion in 2029 at a compound annual growth rate (CAGR) of 7.0%. The projected growth during the forecast period can be attributed to the increasing demand for pharmaceuticals, the rise of combination therapy, growing awareness and healthcare investments, a rising geriatric population, and the increasing number of cancer cases. Key trends expected during this period include advancements in antiemetic therapies, strategic collaborations, innovative drug formulations, the integration of advanced diagnostic tools, and the development of electronic simulation devices.

The increasing number of surgical procedures is expected to drive the growth of the post-operative nausea and vomiting market. Surgical procedures involve medical interventions that utilize tools to diagnose, treat, or remove damaged tissues, organs, or abnormalities through cutting or manipulation. The rise in surgical procedures is attributed to advancements in medical technology, which have made surgeries safer, more effective, and minimally invasive, leading to greater patient acceptance and broader applicability. Effective management of post-operative nausea and vomiting enhances surgical procedures by improving patient comfort, reducing recovery time, minimizing complications, and ensuring smoother post-operative care, ultimately leading to better surgical outcomes. For example, in November 2024, the Australian Institute of Health and Welfare reported that during the 2023-24 period, 771,600 patients were admitted for surgery from public hospital elective surgery waiting lists, reflecting a 4.9% increase compared to 2022-23. This trend highlights the growing number of surgical procedures, which is fueling the expansion of the post-operative nausea and vomiting market.

Companies in the post-operative nausea and vomiting market are focusing on developing critical injectable medications using advanced emulsion formulations and sustained-release technology to improve treatment efficacy and provide prolonged symptom relief for surgical patients. These critical injectable medications are essential drugs administered via injection to deliver immediate and effective treatment for serious or urgent medical conditions. For example, in July 2024, Avenacy, a US-based specialty pharmaceutical company, introduced Palonosetron Hydrochloride Injection in 0.25 mg/5 mL single-dose vials. This formulation helps healthcare providers reduce dosing errors and improve patient safety. The injection is designed to prevent nausea and vomiting induced by chemotherapy and to manage post-operative nausea and vomiting for up to 24 hours following surgery, offering a reliable treatment option for patients at risk of these conditions.

In June 2022, Eagle Pharmaceuticals, Inc., a US-based pharmaceutical company, acquired Acacia Pharma Group plc for an undisclosed amount. This acquisition aims to strengthen Eagle Pharmaceuticals' acute care portfolio and enhance hospital sales capabilities by leveraging its network to promote BARHEMSYS for post-operative nausea and vomiting rescue treatment and BYFAVO for procedural sedation. The deal addresses significant unmet clinical needs and aims to improve patient care. Acacia Pharma Group plc, a UK-based hospital pharmaceutical company, specializes in supportive care treatments for post-operative nausea and vomiting.

Major players in the post-operative nausea and vomiting market are Pfizer Inc., Merck KGaA, Novartis AG, GlaxoSmithKline Plc, Takeda Pharmaceutical Company Limited., Baxter Corporation, Teva Pharmaceutical Industries Ltd., Sandoz Group AG, Daiichi Sankyo Inc., Fresenius Kabi AG, Eisai Co. Ltd., Dr. Reddy's Laboratories, Kyowa Hakko Kirin Taiwan Co. Ltd., Cipla Ltd., Alkem Laboratories Ltd., Eagle Pharmaceuticals Inc., Camurus AB, Helsinn Healthcare SA, Heron Therapeutics Inc., Advacare Pharma.

North America was the largest region in the post-operative nausea and vomiting market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in post-operative nausea and vomiting report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the post-operative nausea and vomiting market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The post-operative nausea and vomiting market consists of revenues earned by entities by providing services such as patient monitoring, anesthesia management, antiemetic drug administration, postoperative care, and clinical counseling. The market value includes the value of related goods sold by the service provider or included within the service offering. The post-operative nausea and vomiting market also includes sales of antiemetic drugs, intravenous fluids, nausea relief patches, oxygen therapy devices, and acupuncture kits. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values and are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Post-Operative Nausea And Vomiting Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on post-operative nausea and vomiting market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

Where is the largest and fastest growing market for post-operative nausea and vomiting ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The post-operative nausea and vomiting market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

Scope

Table of Contents

1. Executive Summary

2. Post-Operative Nausea And Vomiting Market Characteristics

3. Post-Operative Nausea And Vomiting Market Trends And Strategies

4. Post-Operative Nausea And Vomiting Market - Macro Economic Scenario Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics And Covid And Recovery On The Market

5. Global Post-Operative Nausea And Vomiting Growth Analysis And Strategic Analysis Framework

6. Post-Operative Nausea And Vomiting Market Segmentation

7. Post-Operative Nausea And Vomiting Market Regional And Country Analysis

8. Asia-Pacific Post-Operative Nausea And Vomiting Market

9. China Post-Operative Nausea And Vomiting Market

10. India Post-Operative Nausea And Vomiting Market

11. Japan Post-Operative Nausea And Vomiting Market

12. Australia Post-Operative Nausea And Vomiting Market

13. Indonesia Post-Operative Nausea And Vomiting Market

14. South Korea Post-Operative Nausea And Vomiting Market

15. Western Europe Post-Operative Nausea And Vomiting Market

16. UK Post-Operative Nausea And Vomiting Market

17. Germany Post-Operative Nausea And Vomiting Market

18. France Post-Operative Nausea And Vomiting Market

19. Italy Post-Operative Nausea And Vomiting Market

20. Spain Post-Operative Nausea And Vomiting Market

21. Eastern Europe Post-Operative Nausea And Vomiting Market

22. Russia Post-Operative Nausea And Vomiting Market

23. North America Post-Operative Nausea And Vomiting Market

24. USA Post-Operative Nausea And Vomiting Market

25. Canada Post-Operative Nausea And Vomiting Market

26. South America Post-Operative Nausea And Vomiting Market

27. Brazil Post-Operative Nausea And Vomiting Market

28. Middle East Post-Operative Nausea And Vomiting Market

29. Africa Post-Operative Nausea And Vomiting Market

30. Post-Operative Nausea And Vomiting Market Competitive Landscape And Company Profiles

31. Post-Operative Nausea And Vomiting Market Other Major And Innovative Companies

32. Global Post-Operative Nausea And Vomiting Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Post-Operative Nausea And Vomiting Market

34. Recent Developments In The Post-Operative Nausea And Vomiting Market

35. Post-Operative Nausea And Vomiting Market High Potential Countries, Segments and Strategies

36. Appendix

(주)글로벌인포메이션 02-2025-2992 kr-info@giikorea.co.kr
ⓒ Copyright Global Information, Inc. All rights reserved.
PC버전 보기